Mizuho Securities Sticks to Their Buy Rating for Merck & Company (MRK)

Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Merck & Company (MRKResearch Report) yesterday and set a price target of $100.00. The company’s shares closed last Tuesday at $83.72.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 5.8% and a 38.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merck & Company with a $93.10 average price target, an 11.3% upside from current levels. In a report issued on March 22, Wells Fargo also maintained a Buy rating on the stock with a $90.00 price target.

See the top stocks recommended by analysts >>

Merck & Company’s market cap is currently $211B and has a P/E ratio of 16.23.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Merck & Co., Inc. develops pharmaceutical and vaccine products. It also offers healthcare solutions and vaccines addressing animal health. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Read More on MRK:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More